CytomX Therapeutics Inc. | Mutual Funds
Mutual Funds that own CytomX Therapeutics Inc.
SPDR S&P Biotech ETF
1,090,908
2.48%
2,808
0.42%
09/06/2018
Fidelity Growth Company Fund
1,019,921
2.31%
303,132
0.05%
07/31/2018
Vanguard Total Stock Market Index Fund
992,676
2.25%
101,300
0%
07/31/2018
iShares Russell 2000 ETF
806,988
1.83%
-432
0.04%
09/06/2018
Vanguard Extended Market Index Fund
581,990
1.32%
205,668
0.02%
07/31/2018
iShares Nasdaq Biotechnology ETF
510,986
1.15%
-6,678
0.12%
09/06/2018
Fidelity Select Health Care Portfolio
490,520
1.11%
75,500
0.14%
07/31/2018
Fidelity OTC Portfolio
485,000
1.1%
0
0.05%
07/31/2018
T Rowe Price Small Cap Stock Fund
456,700
1.04%
-2,800
0.1%
06/30/2018
iShares Russell 2000 Growth ETF
374,682
0.85%
0
0.07%
09/06/2018
| Address |
151 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.cytomx.com |
| Updated |
07/08/2019 |
| CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. |
